Streetbeat News

Analyst Ratings

WRBY

Analysts have provided various ratings for Warby Parker (NYSE:WRBY) within the last quarter, with an average 12-month price target of $15.5. This average price target has increased by 19.23% over the past month.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 7:00 pm

DOOR

RBC Capital analyst Michael Dahl has maintained a 'Sector Perform' rating on Masonite International (NYSE:DOOR) but lowered the price target from $106 to $87.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:59 pm

HUBS

HubSpot Inc (NYSE:HUBS) reported Q3 revenue of $557.6 million, beating estimates of $534.11 million, and EPS of $1.59, surpassing estimates of $1.24. However, the company's shares fell 5% to $419.85 on Thursday. Post earnings announcement, analysts from Raymond James, Morgan Stanley, Piper Sandler, and RBC Capital revised their price targets for HubSpot.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:59 pm

MGNI

RBC Capital analyst Matthew Hedberg maintains an 'Outperform' rating on Magnite (NASDAQ:MGNI), but has lowered the price target from $15 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:58 pm

JAZZ

RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ), but lowered the price target from $200 to $191.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:56 pm

JAMF

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on Jamf Holding (NASDAQ:JAMF) but lowers the price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:54 pm

JKHY

RBC Capital analyst Daniel Perlin has maintained a 'Sector Perform' rating on Jack Henry & Associates (NASDAQ:JKHY) and lowered the price target from $181 to $161.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:53 pm

RBT

Rubicon Technologies reported lower than expected Q3 revenue results, leading to a drop in its share price. Additionally, Canaccord Genuity downgraded the stock from Buy to Hold and reduced its price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:51 pm

BIIB

Biogen Inc (NASDAQ:BIIB) reported better-than-expected Q3 earnings with sales of $2.53 billion, beating the consensus of $2.39 billion. However, the company revised its FY23 revenues to decline in a low-single-digit percentage versus FY22. Following the earnings announcement, Wells Fargo and RBC Capital increased their price targets on Biogen, while Wedbush cut its price target.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:49 pm

ARM

Analysts from BMO Capital, KeyBanc Capital Markets, Mizuho Securities, and Goldman Sachs remain bullish on Arm Holdings Plc (NASDAQ:ARM) despite concerns over royalty rates. The analysts highlighted the company's strong Q2 results, robust licensing growth, and its position as a global leader in semiconductor IP licensing. However, they noted a lower outlook for mobile royalties due to smartphone weakness. The analysts have set price targets ranging from $60 to $65.

Portfolio Pulse from Anusuya Lahiri

November 09, 2023 | 6:49 pm